An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer
Autor: | Hiroomi Ogawa, Makoto Sohda, Kengo Kuriyama, Takayoshi Watanabe, Yasunari Ubukata, Ken Shirabe, Takehiko Yokobori, Hiroshi Saeki, Makoto Sakai, Arisa Yamaguchi, Hideyuki Saito, Nobuhiro Nakazawa, Akihiko Sano |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Cancer Research medicine.medical_specialty Dehydrogenase Gastroenterology chemistry.chemical_compound Antineoplastic Agents Immunological Stomach Neoplasms Internal medicine Lactate dehydrogenase medicine Humans In patient Blood testing Immune Checkpoint Inhibitors Serum Albumin Aged L-Lactate Dehydrogenase business.industry Albumin Cancer General Medicine Prognosis medicine.disease Elevated serum lactate Nivolumab Oncology chemistry Drug Resistance Neoplasm Disease Progression Female business Biomarkers |
Zdroj: | Anticancer Research. 41:3925-3931 |
ISSN: | 1791-7530 0250-7005 |
Popis: | Background/aim This study clarified the predictive impact of serum biomarkers on therapeutic sensitivity to nivolumab in patients with gastric cancer (GC). Patients and methods The outcomes of 27 patients who received nivolumab to treat postoperative recurrent or unresectable advanced GC were reviewed. Blood testing was performed immediately before and after two courses of nivolumab. We also focused on the rate of change of each blood variable. Results The decrease in albumin (Alb) levels (p=0.035) and increase in lactate dehydrogenase (LDH) levels (p=0.012) after two courses of nivolumab were significantly larger in patients with disease progression. Furthermore, therapeutic resistance was significantly associated with an elevated LDH-to-Alb ratio (LAR) after two courses of nivolumab. Conclusion Decreased Alb or increased LDH levels after two courses of nivolumab predicted nivolumab sensitivity in patients with GC. An increased LAR was a meaningful predictor of nivolumab resistance. |
Databáze: | OpenAIRE |
Externí odkaz: |